As a result of January–November 2025, the Russian retail market for enterosorbent medicines (group A07B under the EphMRA classification) exceeded RUB 13.1 billion (at retail prices, including VAT). Total consumer spending in the category grew by 7.9% compared with the same period of 2024. Over the first eleven months of 2025, buyers purchased 50 million packs of these medicines; however, natural consumption within the group declined by 7.4% year on year. Notably, for several consecutive years physical demand for intestinal adsorbents has been steadily decreasing, while consumer expenditure has continued to rise. This trend is driven by the gradual withdrawal of low-priced products from the market, with the sharpest decline in demand observed for activated charcoal and povidone-based medicines. At the same time, growth in sales of products from the upper price segment, together with inflationary factors, has led to a significant increase in the average pack price. In January–November 2025, it amounted to RUB 262 (at retail prices, including VAT), which is 73% higher than in 2022.

Demand for adsorbing agents typically increases during the summer months and ahead of the New Year holidays. In the past year, peak summer sales were recorded in August, when consumers purchased around 5.2 million packs worth RUB 1.4 billion. However, these figures were lower than those recorded in August 2024, by 2% in value terms and by 10% in physical terms. In November, demand in packs for the analysed group declined by 5% compared with the previous month and by 2.9% compared with November 2024.

According to the Audit of Retail Pharmaceutical Sales in Russia (total sell out) database of the analytical company RNC Pharma, more than half of physical sales in the group (52%) are generated by activated charcoal products; nevertheless, their value share does not exceed 12.2%. It should be noted that the share of activated charcoal has been decreasing every year: for comparison, in 2022 it accounted for more than 60% of total physical sales of enterosorbents. In total, from January to November 2025, the retail market segment (including the online channel with home delivery) comprised 25 brands of intestinal adsorbents from 29 corporations, with three brands having entered the market over the past two years.

The group leader remains Enterosgel by Pharmasil. The product accounts for more than 33% of total category spending, and compared with January–November 2024, the brand showed value growth of 10%. Polysorb, produced by the company of the same name, retained second place, with a 25.7% share in value terms and 13.4% in physical terms. Compared with January–November 2024, demand for this product declined by 8% in physical terms, while consumer spending increased by 5%. Third place is occupied by unbranded activated charcoal products from nine different companies. Over the year, physical demand for these products fell by 10%, while total spending increased by 4% due to rising prices.

Notably, among the brands in the top ten, only two demonstrated growth in physical sales volumes. These include Filtrum by AVVA Pharmaceutical (+4% in packs) and the new product by Grotex — Solosorb (INN: polymethylsiloxane polyhydrate). Sales of this direct analogue of Enterosgel began at the end of 2024; as a result, compared with January–November 2024, its sales increased by a factor of 1,369.

Outside the top ten, dioctahedral smectite products from several manufacturers can also be highlighted. Taken together, they demonstrated value growth of 36.5% compared with January–November 2024.

Table. Top 10 enterosorbent brands (group A07B — intestinal anti-diarrhoeal adsorbents under the EphMRA classification) by value sales on the Russian retail pharmaceutical market in January–November 2025